BioSpace News Archive

Aytu BioScience, Inc. (NASDAQ:AYTU) a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal first quarter ended September 30, 2020 on November 12, 2020, at 4:30 p.m. ET.

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first nine months of 2020 on Thursday, 12 November 2020.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC) daratumumab utilizing ENHANZE ® will be the subject of presentations at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtuall

$38.8M in Rubraca ® (rucaparib) global sales for Q3 2020; net product revenue up 3% over Q3 2019 Global net product revenue guidance provided for Q4 2020 in a range of $38M to $40M Restructuring U.S. commercial organization to adopt hybrid strategy elevating digital programming and peer-to-peer interactions

Xenetic Biosciences, Inc. announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 6th Annual Israel Conference on Tuesday, November 12, 2020 at 8:00 AM EST.

Thirty-five abstracts with clinical trial data to be presented, featuring findings across psoriatic arthritis (PsA), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) Sixteen abstracts focus on TREMFYA® (guselkumab) in adults with active PsA, including 52-week safety and efficacy data, spinal disease-related endpoints, as well as analyses that highlight patient-reported outcome measures including fatigue

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced that management will participate in the upcoming virtual investor conferences in November:

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that Otis Brawley, M.D., has been appointed to PDS Biotech’s Board of Directors.

Achieved Oxbryta®(voxelotor)net revenues of $36.9millionwith more than 1,000new patient prescriptionsin the third quarter and net revenues of $82.5 millionthroughfirst nine months of 2020

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results for the three and nine months ended September 30, 2020.